EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeted Drug Delivery in Periorbital Non-Melanocytic Skin Malignancies

Benedetta Tirone, Anna Scarabosio iD, Pier Luigi Surico iD, Pier Camillo Parodi, Fabiana D'Esposito iD, Alessandro Avitabile iD, Caterina Foti, Caterina Gagliano iD, Marco Zeppieri iD

Bioengineering · 15.10.2024 · 11 (10) · 1029

DOI: 10.3390/bioengineering11101029 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioengineering, online erschienen am 15.10.2024. Verfasst von Benedetta Tirone und 8 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology and Venerology Section, Department of Precision and Regenerative Medicine and Ionan Area (DiMePRe-J), University of Bari Aldo Moro, 70124…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted drug delivery has emerged as a transformative approach in the treatment of periorbital skin malignancies, offering the potential for enhanced efficacy and reduced side effects compared to traditional therapies. This review provides a comprehensive overview of targeted therapies in the context of periorbital malignancies, including basal cell carcinoma, squamous cell carcinoma, sebaceous gland carcinoma, and Merkel cell carcinoma. It explores the mechanisms of action for various targeted therapies, such as monoclonal antibodies, small molecule inhibitors, and immunotherapies, and their applications in treating these malignancies. Additionally, this review addresses the management of ocular and periocular side effects associated with these therapies, emphasizing the importance of a multidisciplinary approach to minimize impact and ensure patient adherence. By integrating current findings and discussing emerging trends, this review aims to highlight the advancements in targeted drug delivery and its potential to improve treatment outcomes and quality of life for patients with periorbital skin malignancies.

Schlagwörter

Stichwörter der Autor:innen

Merkel cell carcinomabasocellular carcinomaperiorbital skin malignanciessquamocellular carcinomatargeted drug delivery systemstargeted drugs

Autor:innen und Institutionen

  • Dermatology and Venerology Section, Department of Precision and Regenerative Medicine and Ionan Area (DiMePRe-J), University of Bari Aldo Moro, 70124 Bari, Italy.
  • Clinic of Plastic and Reconstructive Surgery, Ospedale Santa Maria della Misericordia, 33100 Udine, Italy.
  • Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
  • Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, MA 02114, USA.
  • Department of Ophthalmology, Campus Bio-Medico University, 00128 Rome, Italy.
  • Imperial College Ophthalmic Research Group (ICORG) Unit, Imperial College, 153-173 Marylebone Rd, London NW15QH, UK.

ORCID-Profile: Anna Scarabosio, Pier Luigi Surico, Fabiana D'Esposito, Alessandro Avitabile, Caterina Gagliano, Marco Zeppieri

Zitieren

APA

Tirone, B., Scarabosio, A., Surico, P. L., Parodi, P. C., D'Esposito, F., Avitabile, A., Foti, C., Gagliano, C., & Zeppieri, M. (2024). Targeted Drug Delivery in Periorbital Non-Melanocytic Skin Malignancies. Bioengineering, 11(10), 1029. https://doi.org/10.3390/bioengineering11101029

Vancouver

Tirone B, Scarabosio A, Surico PL, Parodi PC, D'Esposito F, Avitabile A, et al. Targeted Drug Delivery in Periorbital Non-Melanocytic Skin Malignancies. Bioengineering. 2024;11(10):1029. doi:10.3390/bioengineering11101029

BibTeX
@article{Tirone2024,
  author = {Tirone, Benedetta and Scarabosio, Anna and Surico, Pier Luigi and Parodi, Pier Camillo and D'Esposito, Fabiana and Avitabile, Alessandro and Foti, Caterina and Gagliano, Caterina and Zeppieri, Marco},
  title = {Targeted Drug Delivery in Periorbital Non-Melanocytic Skin Malignancies},
  journal = {Bioengineering},
  year = {2024},
  volume = {11},
  number = {10},
  pages = {1029},
  doi = {10.3390/bioengineering11101029}
}
Kostenlos starten →